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OBJECTIVES The aim of this study was to assess whether small creatine kinase-MB isoenzyme (CK-MB)
elevations after percutaneous coronary intervention (PCI) affect the subsequent mortality risk.
BACKGROUND Several studies have evaluated the relationship of CK-MB levels after PCI with the
subsequent risk of death. While there is consensus that elevations exceeding 5 times the upper
limit of normal increase mortality significantly, there is uncertainty about the exact clinical
impact of smaller CK-MB elevations.
METHODS We performed a meta-analysis of seven studies with CK-MB measurements and survival
outcomes on 23,230 subjects who underwent PCI. Data were combined with random effects
models.
RESULTS Mean follow-up was 6 to 34 months per study. By random effects, 19% (95% confidence
interval [CI], 16% to 23%) had one- to five-fold CK-MB elevations, while only 6% (95% CI,
5% to 9%) had 5-fold elevations. Compared with subjects with normal CK-MB, there was
a dose-response relationship with relative risks for death being 1.5 (95% CI, 1.2 to 1.8, no
between-study heterogeneity) with one- to three-fold CK-MB elevations, 1.8 (95% CI, 1.4
to 2.4, no between-study heterogeneity) with three- to five-fold CK-MB elevations, and 3.1
(95% CI, 2.3 to 4.2, borderline between-study heterogeneity) with over five-fold CK-MB
elevations (p  0.001 for all).
CONCLUSIONS Any increase in CK-MB after PCI is associated with a small, but statistically and clinically
significant, increase in the subsequent risk of death. (J Am Coll Cardiol 2003;42:1406–11)
© 2003 by the American College of Cardiology Foundation
Microvascular coronary embolization, either spontaneous or
iatrogenic, is now a well-recognized clinical entity (1).
Creatine kinase-MB isoenzyme (CK-MB) elevation is
common after percutaneous coronary intervention (PCI)
and, if sought, can be detected in up to 25% of cases (2) or
even a larger percentage if more sensitive markers, such as
troponin T or I, are used (3,4). Extensive cardiac enzyme
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release after PCI has been correlated with late mortality in
several studies (5,6). Still, however, the amount of increase
that is clinically relevant and the threshold level of CK-MB
that has prognostic significance remain elusive (7). Post-
PCI CK-MB isoenzyme increases up to 5 times the upper
limit of normal have typically not been found to be
statistically significant for predicting survival, and their
clinical meaning has been questioned (7,8). Nevertheless,
the majority of post-PCI CK-MB elevations are in this
range; most are actually in the range of 1 to 3 times the
upper limit of normal (5). Previous studies have had
inadequate power to evaluate the exact impact of such
enzyme elevations on the subsequent risk of death. Thus, we
performed a comprehensive meta-analysis of all pertinent
studies to clarify the clinical significance of small CK-MB
elevations after PCI.
METHODS
Eligibility and search strategy. The meta-analysis in-
cluded studies reporting data on post-PCI CK-MB values
in relationship to the subsequent risk of death during
follow-up. Abstracts were not eligible. All types of PCI
were eligible including percutaneous transluminal coronary
angioplasty (PTCA), stent placement, atherectomy (direc-
tional, rotational, extraction), and excimer laser. Whenever
study reports included both patients with and without PCI,
only the first group was used. The meta-analysis focused on
the strata of one- to three-fold elevation and three- to
five-fold elevation compared with normal CK-MB, but also
examined data on subjects with over five-fold CK-MB
elevations to address whether there is a clear dose-response
relationship. Because it is unclear whether the potential
prognostic effect of CK-MB elevations may change in the
very long-term due to competing causes of death or may be
affected by extensive missing information and censoring, we
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focused on studies with mean follow-up between three
months and three years; whenever reports with different
follow-up were available from the same study, we selected
the data closest to six months. We excluded studies with CK
data without additional information on deaths according to
MB isoenzyme strata. Potentially eligible studies were
carefully scrutinized for overlap of subjects. Reports provid-
ing information on a subgroup of a larger population
described in another report were excluded, while, in cases of
considerable partial overlap of subjects between reports, we
generally retained only the largest study with available data
to avoid double counting.
We identified eligible studies in MEDLINE and EM-
BASE (last search updated February 2003) using the
keywords creatine kinase AND angioplasty or stent. We
also screened bibliographies of retrieved studies and com-
municated with experts.
Data. For each study we recorded study design, the types of
PCI employed, and the number of subjects in CK-MB
strata (normal, 1- to 3-fold elevation, 3- to 5-fold elevation,
5-fold elevation). The outcome of interest was mortality
during the available follow-up, excluding acute events dur-
ing the PCI. Deaths were recorded per stratum. Whenever
exact numbers were not provided, we approximated risk
ratios and 95% confidence intervals (CI) from Kaplan-
Meier curves and other presented information. Two inde-
pendent investigators extracted data, and discrepancies were
resolved with consensus.
Analysis. Proportions of the subjects in each CK-MB
stratum across studies were synthesized with random effects
models. We evaluated separately the risk ratio for mortality
with one- to five-fold, one- to three-fold, three- to five-
fold, and 5-fold elevation versus normal CK-MB. Risk
ratios for mortality were estimated in each study, and
between-study heterogeneity was estimated using the Q
statistic (significant for p  0.10) (9). Risk ratios were then
combined using the general variance method, weighting
each log-transformed risk ratio by the inverse of its variance
(fixed effects model) or by the inverse of the sum of its
variance plus the between-study variance (random effects
model) (9). In the absence of between-study heterogeneity,
the two models coincide, while random effects are more
appropriate when there is between-study heterogeneity.
Absolute risk differences for mortality across different
CK-MB strata were calculated by multiplying the random
effects relative risk increase (risk ratio 1) times the
observed death rates in the stratum of subjects with normal
CK-MB after PCI. Typical observed death rates were based
on Kaplan-Meier estimates at one and two years of
follow-up in studies that provided such information.
Analyses were conducted in SPSS 10.0 (SPSS Inc.,
Chicago, Illinois) and in Meta-Analyst (Joseph Lau, Bos-
ton, Massachusetts). The p values are two-tailed.
RESULTS
Eligible studies. We identified 23 potentially eligible re-
ports (5,6,8,10–29). Fifteen were excluded up front (CK-
based strata [n  4] [15–18]; entirely included in larger
studies [n  6] [19–24]; partial overlap with other larger
studies with available data [n  5] [25–29]). Another large
study (8) provided neither separate information for all the
pertinent CK-MB strata nor absolute numbers of deaths,
and it largely overlapped with another study that provided
detailed pertinent data for the meta-analysis. We were
unable to obtain additional clarifications from the primary
Table 1. Characteristics of Included Studies
Study (yr) n* Age (yrs)
Male
(%)
Procedures Involved
(% of Total Number)
Reported Protocol for Obtaining
CK-MB Measurements
Brener (2002) 3,573 64 (mean) 71 Various (not specified) At 8 h, next morning and with suspected ischemia
Akkerhuis (2002)† 8,838 60 (median) 69 PTCA (81%), stent (8%), DCA (6%),
other (5%)
Variable, used peak value within 48 h
Stone (2001) 7,147 64 (mean) 70 Stent (37%), atheroablation (37%),
both (17%), PTCA (9%)
At baseline, 8–12 and 16–24 h; if abnormal, also
every 8–12 h until normalized
Kini (1999) 1,675 64 (mean) 68 Stent (29%), HRSA (25%), both
(32%), PTCA (10%), other (4%)
At baseline, 6–8 and 16–24 h
Baim (1998) 956 58 (mean) 79 DCA (50%), PTCA (50%) At baseline, 4–6 h, and hospital discharge or 24 h
Harrington (1995) 483 no data no data DCA (58%), PTCA (42%) At 12 and 24 h and with suspected ischemia
Kugelmass (1994) 558 60 (mean) 82 Stent (51%), DCA (49%) At baseline and 24 h; if abnormal, repeated until peak
*With available CK-MB data; †composite data from five trials (PURSUIT, IMPACT-II, EPIC, EPILOG, CAPTURE).
CK-MB  creatine kinase-MB isoenzyme; DCA  directional coronary atherectomy; HSRA  high-speed rotational atherectomy; PTCA  percutaneous transluminal
coronary angioplasty.
Abbreviations and Acronyms
CI  confidence interval
CK-MB  creatine kinase-MB isoenzyme
EPIC  Evaluation of IIb/IIIa Platelet Receptor
Antagonist 7E3 in Preventing Ischemic
Complications trial
EPILOG  Evaluation in PTCA to Improve Long-
term Outcome with Abciximab
Glycoprotein IIb/IIIa Blockade trial
IMPACT-II  Integrilin (eptifibatide) to Minimize
Platelet Aggregation and Coronary
Thrombosis-II study
PCI  percutaneous coronary intervention
PTCA  percutaneous transluminal coronary
angioplasty
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investigators. Nevertheless, this study was included in a
sensitivity analysis for the comparison of one- to five-fold
CK-MB elevation versus normal controls.
The seven eligible studies with complete pertinent data
(5,6,10–14) totaled 23,230 subjects (Table 1). Four of the
eligible studies clearly stated that they excluded patients
with major complications during catheterization (6,10,11,13),
while three studies (5,12,14) did not comment on whether
any such patients were included. All studies included a
preponderance of males with a mean or median age between
58 to 65 years. A variety of PCI types had been employed in
each study (Table 1). The protocol for measuring CK-MB
in each study is shown in Table 1.
The seven eligible studies included 16,133 subjects with
normal CK-MB, 3,981 subjects with one- to three-fold,
1,124 subjects with three- to five-fold, and 1,992 subjects
with over five-fold CK-MB elevations (Table 2). The
percentage of subjects with one- to five-fold CK-MB
elevation (range, 8.6% to 27.7%) exceeded the percentage of
subjects with larger CK-MB elevations (range, 2.4% to
11.8%) across all studies. By random effects, the overall
percentage was 19% (95% CI, 16% to 23%) for one- to
five-fold CK-MB elevations versus 6% (95% CI, 5% to 9%)
for CK-MB elevations exceeding five-fold the upper limit of
normal.
Meta-analysis. There was no significant between-study
heterogeneity in the risk ratio estimates in any of the
contrasts of CK-MB strata (p 0.10), with the exception of
the comparison between subjects with over five-fold
CK-MB elevations against subjects with normal CK-MB
where borderline between-study heterogeneity was seen (p
 0.10). One- to five-fold CK-MB elevations conferred a
significant increase in the risk of mortality with an overall
risk ratio of 1.5 (95% CI, 1.3 to 1.8, p  0.001; Fig. 1A).
There was a dose-response: the summary risk ratio was 1.5
for one- to three-fold elevation (95% CI, 1.2 to 1.8, p 
0.001; Fig. 1B) and 1.8 for three- to five-fold elevation
(95% CI, 1.4 to 2.4, p 0.001; Fig. 1C). Fixed and random
effects coincided, and the results were very consistent across
studies. The dose-response was also clear when subjects
with over five-fold CK-MB were considered. Their risk
ratio compared with normal CK-MB subjects was 3.1 (95%
CI, 2.3 to 4.2, p  0.001) by random effects calculations
(Fig. 1D). There was a suggestion that for this contrast the
risk ratio estimates tended to be higher in three (5,10,12) of
the four (5,10,12,14) studies with relatively shorter
follow-up.
A sensitivity analysis including Ellis et al. (8) in the one-
to five-fold versus normal CK-MB analysis yielded similar
results (summary risk ratio 1.6, 95% CI, 1.3 to 1.8, p 
0.001). There was no significant difference in the risk ratio
estimates of small versus larger studies or in early published
versus recent studies in any of the considered contrasts (not
shown).
Based on Kaplan-Meier plots, the one-year and two-year
mortality risks among patients with normal CK-MB was
3% to 4% and 6% to 8%, respectively, in studies that
provided such data (Table 2). For a cohort with a death rate
of 3.5% per year among subjects with normal CK-MB, the
absolute increase in the mortality risk among patients with
one- to three-fold, three- to five-fold, and5-fold CK-MB
elevations after PCI would be 1.7%, 2.8%, and 7.4% per
year, respectively.
DISCUSSION
This meta-analysis based on data from over 23,000 subjects
clarifies the clinical significance of small CK-MB elevations
after PCI. Any CK-MB increase is associated with a
potential increase in the subsequent risk of death during
follow-up. One- to three-fold CK-MB elevations increase
the risk of death by approximately 50%. In a step-wise
fashion, the risk is increased by 80% with three- to five-fold
CK-MB elevations and is tripled with over five-fold
CK-MB elevations.
Prior investigations had clearly stressed the adverse prog-
nosis of subjects with CK-MB increases exceeding 5 times
(or even 8 times) the upper limit of normal (6,8). However,
such CK-MB elevations are on average three times less
frequent than elevations in the one- to five-fold range.
Thus, the impact of “small” CK-MB elevations on excess
mortality on a population basis is not negligible when
Table 2. Distribution of CK-MB Values and Follow-Up
Study (yr)
Percent With
CK-MB Increase Mean
Follow-Up
(months)
Death Rate
(Normal CK-MB)
None 1–3 3–5 >5 1 Year (%)* 2 Years (%)*
Brener (2002) 61.5 21.9 5.8 10.7 34 3.7 6.0
Akkerhuis (2002)† 74.1 15.6 3.4 6.9 6 ND ND
Stone (2001) 62.7 19.4 6.1 11.8 17 3.4 7.0
Kini (1999) 81.3 12.6 3.7 2.4 13 ND ND
Baim (1998) 74.7 14.1 4.6 6.6 12 ND ND
Harrington (1995) 69.6‡ 11.2‡ 11.4 7.8 12 ND ND
Kugelmass (1994) 87.3 5.8 2.8 4.1 24 4.0 8.0
*Estimated risk of death based on Kaplan-Meier plots for patients who had normal CK-MB after percutaneous coronary
intervention; †composite data from five trials (PURSUIT, IMPACT-II, EPIC, EPILOG, CAPTURE); ‡subjects with up to
two-fold elevation are included in the “None” category.
CK-MB  creatine kinase-MB isoenzyme; ND  no data available.
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compared against the impact of the more unusual high-level
increases.
Approximately one in five subjects undergoing PCI will
have an elevation of CK-MB by one- to five-fold, and one
in 15 subjects will have an even larger increase. Stent and
atheroablative procedures may confer a higher risk of
CK-MB release than PTCA (10,12,13), and combined
procedures may increase the risk even further (6). Saphe-
nous vein graft interventions may also have a higher risk of
CK-MB release (27). In certain clinical settings, such as
diabetes mellitus and states of elevated C-reactive protein or
other inflammatory markers, patients are particularly prone
to coronary microembolization, either spontaneous or iat-
rogenic (1). We could not address separately the risk of
death in these subgroups according to CK-MB strata.
However, it is possible that the absolute excess mortality
may be even larger in high-risk subpopulations.
We should acknowledge that the studies included in the
meta-analysis used a considerable variety of revasculariza-
tion procedures. Even with 23,000 patients, the meta-
analysis is not fully powered to examine whether there are
any differences on what subclinical CK-MB elevations mean
for different types of PCI. However, the absence of
between-study heterogeneity in the risk ratios suggests that
any such differences, if present, may not be very prominent.
Another issue is whether the impact of the CK-MB
elevations on mortality risk remains constant over long
durations of follow-up. This seems to be the case at least for
two to three years with minor CK-MB elevations; CK-MB
may be an index of myocardial damage that carries prog-
nostic information in the long-term even with small in-
creases. For high CK-MB elevations, other investigators
have noted a more prominent adverse prognostic impact in
the early months after PCI (6), and our data, although not
definitive, are also consistent with this perspective. Finally,
it would be interesting to evaluate also with large-scale
studies the ability of other myocardial enzymes (3,4) to
predict long-term outcomes after PCI.
It has been speculated whether periprocedural emboliza-
tion carries the exact same adverse prognostic implications
as with spontaneous myocardial necrosis (5). Other inves-
tigators observed two- to 2.5-fold increases in the risk of
death with one- to five-fold CK-MB elevations after spon-
taneous infarction and suggested that iatrogenic and spon-
taneous CK-MB elevations may have similar implications
(5). Although our risk ratio estimates are somewhat smaller,
Figure 1. Relative risk of death with various creatine kinase-MB isoenzyme (CK-MB) elevations. Each study is shown by the risk ratio estimate and the
corresponding 95% confidence interval. Also shown is the summary estimate for all studies. (A) One- to five-fold elevation versus normal CK-MB. (B)
Three- to five-fold elevation versus normal CK-MB. (C) Three- to five-fold elevation versus normal CK-MB. (D) 5-fold elevation versus normal
CK-MB.
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and the CIs exclude a doubling in mortality risk with one-
to five-fold CK-MB elevations, any enzyme release post-
PCI does seem to affect prognosis. The level of post-PCI
CK-MB elevation that carries an adverse prognosis has been
debated (7). Based on our findings and in concordance with
the recent redefinition criteria of myocardial infarction (30),
we conclude that any increase in CK-MB post-PCI is
associated with a small, but significant, increase in the
subsequent risk of death. Given that minor elevations are far
more common than more pronounced CK-MB increases,
their mortality impact may be considerable in the popula-
tion of patients undergoing PCI.
We should acknowledge that our meta-analysis focuses
on the importance of mostly asymptomatic elevations of
CK-MB after PCI as contrasted to major symptomatic
periprocedural myocardial infarctions. We have clearly doc-
umented an increasing long-term mortality risk with in-
creasing levels of CK-MB elevation. Nevertheless, this risk
would have to be weighted against the anticipated benefit of
the PCI and should not lead to abandoning PCI, when this
is clearly indicated. For example, the risk conferred from
small CK-MB elevations may be negligible compared with
the benefit obtained from revascularization in a patient with
tight proximal left anterior descending stenosis with unsta-
ble angina and a positive stress test. Risks and benefits
should be carefully weighted in each case. Moreover, we
should caution that the observed association between
CK-MB elevation and subsequent mortality risk does not
necessarily prove causality for this relationship. The
CK-MB elevation may indeed reflect direct myocardial
damage in some cases. However, in other cases it may
simply be a surrogate for more extensive disease or more
vulnerable plaques, and the subsequent increased mortality
may not be directly linked to the original PCI-related
microinfarction. New strategies should be considered to try
to minimize the risk of cardiac events and death after PCI.
For example, use of platelet glycoprotein IIb/IIIa receptor
antagonists has recently been shown to decrease the risk of
death both in the short- and long-term in patients under-
going PCI (31).
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